Findings

What do systematic reviews say?

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC

The review found no eligible studies for this question.

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.99 [0.84, 1.17]
2 studies · 1451 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Progression‐free survival (PSF) · newly‐diagnosed EOC

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.88 [0.77, 1]
2 studies · 1451 participants
Moderate

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

QoL · newly‐diagnosed EOC

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1340 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.99 [0.88, 1.12]
4 studies · 1712 participants
Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
HR 0.94 [0.74, 1.2]
2 studies · 1243 participants
Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.59 [0.44, 0.8]
4 studies · 1712 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis probably leads to lower recurrent venous thromboembolism (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
HR 0.49 [0.31, 0.78]
2 studies · 1243 participants
Moderate

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in major bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 1.09 [0.55, 2.12]
4 studies · 1712 participants
Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Minor bleeding (main analysis ‐ active cancer) · patients with cancer with venous thromboembolism

It is very uncertain whether low molecular weight heparin secondary prophylaxis changes minor bleeding (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (very low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.78 [0.47, 1.27]
4 studies · 1712 participants
Very low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism

Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.52, 1.69]
1 study · 138 participants
Low

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

Resolution of daytime urinary incontinence · children aged 5 to 16 years with daytime urinary incontinence

Voiding education with uroflow feedback and urotherapy showed no clear difference in resolution of daytime urinary incontinence at 6 to 12 months after 6… compared with urotherapy alone (low certainty).

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
RR 1.13 [0.87, 1.45]
3 studies · 151 participants
Low

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

Frequency of incontinence episodes · children aged 5 to 16 years with daytime urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

Objective measurement of volume of incontinent episodes · children aged 5 to 16 years with daytime urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 16 years with daytime urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

Quality of life measurements · children aged 5 to 16 years with daytime urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Voiding education with uroflow feedback and urotherapy vs urotherapy alone

Adverse effects · children aged 5 to 16 years with daytime urinary incontinence

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 133 participants
GRADE not reported

Enhanced educational intervention and structured follow‐up vs standard education

Time to occurrence of new ulcer · s

The review found no eligible studies for this question.

1 finding from 1 review

Patient and lay carer education for preventing pressure ulceration in at‐risk populations 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Enhanced educational intervention and structured follow‐up vs standard education

Proportion of participants developing a new ulcer · s

The review found no eligible studies for this question.

1 finding from 1 review

Patient and lay carer education for preventing pressure ulceration in at‐risk populations 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found